Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: A systematic review and meta-analysis

Annals of Clinical Microbiology and Antimicrobials

Volumn 15, Issue 1, 2016, Pages

  Agyeman, Akosua Adom ^a   Ofori Asenso, Richard ^a  

^a Research Unit   (Ghana)

Author keywords

Drug therapy; Extensively drug resistant; Infectious diseases; Linezolid; Meta analysis; Multi drug resistance; Tuberculosis

Indexed keywords

LINEZOLID; TUBERCULOSTATIC AGENT;

AFRICA; ANEMIA; BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; INCIDENCE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW; VOMITING; BONE MARROW CELL; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; POLYNEUROPATHY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; LINEZOLID; MYCOBACTERIUM TUBERCULOSIS; MYELOID CELLS; POLYNEUROPATHIES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 85007424289     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-016-0156-y     Document Type: Review

References (60)

1. WHO. Global tuberculosis report 2015. http://www.apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1 Accessed 2 Feb 2016.
2. Maartens G, Wilkinson RJ. Tuberculosis. Lancet. 2007;307(9604):2030-43.
3. WHO. Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/Accessed 2 Feb 2016.
4. WHO. Tuberculosis: the global burden 2005. http://www.who.int/tb/publications/tb_global_facts_sep05_en.pdf Accessed 2 Feb 2016.
5. Reid A, Grant AD, White RG, Dye C, Vynnycky E, Fielding K, Churchyard G, Pillay Y. Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention. Int J Tuberc Lung Dis. 2015;19(1):5-9.
6. WHO. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81(45):425-32.
7. WHO. Multidrug-resistant tuberculosis (MDR-TB). http://www.who.int/tb/challenges/mdr/en/Accessed 2 Feb 2016.
8. Matteelli A, Roggi A, Carvalho AC. Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol. 2014;6:111-8.
9. WHO. Multi-drug resistant tuberculosis (MDR-TB): 2015 update http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf Accessed 3 Feb 2016.
10. Diel R, Nienhaus A, Lampenius N, Rüsch-Gerdes S, Richter E. Cost of multi drug resistance tuberculosis in Germany. Respir Med. 2014;108(11):1677-87.
11. StopTBPartnership. Global plan to stop TB, 2011-2015 http://www.stoptb. org/global/plan/plan1115.asp Accessed 9 Feb 2016.
12. WHO. Towards universal access to diagnosis and treatment of multidrugresistant and extensively drug resistant tuberculosis by 2015: WHO progress report 2011. Geneva: WHO; 2011 (WHO/HTM/TB/2011.3).
13. Alffenaar JWC, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AMA, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet. 2010;49(8):559-65.
14. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J. 2015;45:25-9.
15. Field SK, Fisher D, Jarand JM, et al. New treatment options for multidrugresistant tuberculosis. Ther Adv Respir Dis. 2012;6:255-68.
16. Alcala L, Ruiz-Serrano JM, Turegano CP, de Viedma GD, Diaz-Infantes M, Marin-Arriaza M, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2003;47(1):416-7.
17. Guna R, Munoz C, Dominguez V, Garcia-Garcia A, Galvez J, de Julian-Ortiz J, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother. 2005;55(6):950-3.
18. Yang C, Hong L, Wang D, Meng X, He J, Tong A, et al. In vitro activity of linezolid against clinical isolates against Mycobacterium tuberculosis, including multi-drug resistant and extensively drug-resistant strains from Beijing, China. Jpn J Infect Dis. 2012;65:240-2.
19. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447-54.
20. Jaramillo E, Weyer K, Raviglione M. Linezolid for extensively drug-resistant tuberculosis. N Engl J Med. 2013;368(3):290.
21. Agyeman A, Ofori-Asenso R. Linezolid for the treatment of multi-drug and extensively drug resistant tuberculosis: a systematic review on efficacy and toxicity. Internet J Pharmacol. 2014;13(1).
22. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430-42.
23. Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, Liu Y. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603-15.
24. Whitlock EP, Lin JS, Chou R, Shekelle P, Robinson KA. Using existing systematic reviews in complex systematic reviews. Ann Intern Med. 2008;148(10):776-82.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9.
26. Wikipedia. Linezolid. https://www.en.wikipedia.org/wiki/Linezolid Accessed 2 Feb 2016.
27. Chan K, Bhandari M. Three-minute critical appraisal of a case series article. Indian J Orthop. 2011;45(2):103-4.
28. Law M, Stewart D, Pollock N, Letts L, Bosh J, Westmorland M. Critical review form-quantitative studies. McMaster University 1998 (28th July, 1998). http://www.srs-mcmaster.ca/wp-content/uploads/2015/04/Critical-Review-Form-Quantitative-Studies-English.doc. Accessed 1 Jan 2016.
29. Deenadayalan Y, Perraton L, Machotka Z, Kumar S. Day therapy programs for adolescents with mental health problems: a systematic review. Internet J Allied Health Sci Pract. 2010;8(1):1-14.
30. WHO. Treatment of tuberculosis: guidelines 2010 http://www.whqlibdoc. who.int/publications/2010/9789241547833_eng.pdf. Accessed 2 Feb 2016.
31. TBOnline. Linezolid. http://www.tbonline.info/posts/2011/8/24/linezolid/Accessed 2 Feb 2016.
32. StatsDirect. Proportion meta-analysis http://www.statsdirect.com/help/default.htm#meta_analysis/proportion.htm. Accessed 4 February 2016.
33. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in Meta-analyses. Br Med J. 2003;327(7414):557-60.
34. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002;31(1):88-95.
35. Abbate E, Vescovo M, Natiello M, Cufre M, Garcia A, Gonzalez Montaner P, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother. 2012;67(2):473-7.
36. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-2006. J Antimicrob Chemother. 2010;65(4):775-83.
37. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. Case series report of a linezolid-containing regimen for extensively drugresistant tuberculosis. Chest. 2008;134(1):187-92.
38. De Lorenzo S, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB. On linezolid efficacy and tolerability. Eur Respir J. 2012;39(3):770-2.
39. Fortún J, Martín-Dávila P, Navas E, Pérez-Elías MJ, Cobo J, Tato M, De la Pedrosa EG, Gómez-Mampaso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2005;56(1):180-5.
40. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009;64(2):388-91.
41. Koh WJ, Kang YR, Jeon K, Jung Kwon O, Lyu J, Kim WS, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67(6):1503-7.
42. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508-18.
43. Liu Y, Bao P, Wang D, Li Y, Tang L, Zhou Y, Zhao W. Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Jpn J Infect Dis. 2015;68(3):244-7.
44. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C, TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34(2):387-93.
45. Nam HS, Koh WJ, Kwon OJ, Cho SN, Shim TS. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2009;33(1):92-3.
46. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrugresistant tuberculosis. J Antimicrob Chemother. 2006;58(3):701-4.
47. Roongruangpitayakul C, Chuchottaworn C. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand. J Med Assoc Thai. 2013;96(10):1273-82.
48. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2010;50(1):49-55.
49. Singla R, Caminero JA, Jaiswal A, Singla N, Gupta S, Bali RK, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J. 2012;39(4):956-62.
50. Tang SJ, Zhang Q, Zeng LH, Sun H, Gu J, Hao XH, et al. Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis. Jpn J Infect Dis. 2011;64(6):509-12.
51. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, Wu M, Zen L, Sun H, Liu Y, Gu J, Lin F, Wang X, Zhang Z. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161-70.
52. Tse-Chang A, Kunimoto D, Der E, Ahmed R. Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: a retrospective case review. Can J Infect Dis Med Microbiol. 2013;24(3):e50-2.
53. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR-and XDR-TB: an Indian perspective. Eur Respir J. 2010;35:936-8.
54. Villar M, Sotgiu G, D'Ambrosio L, Raymundo E, Fernandes L, Barbedo J, et al. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur Respir J. 2011;38(3):730-3.
55. Von Der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect. 2006;52(2):92-6.
56. Xu HB, Jiang RH, Li L, Xiao HP. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis. 2012;16(3):358-63.
57. Zhang L, Pang Y, Yu X, Wang Y, Gao M, Huang H, Zhao Y. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection. 2014;42(4):705-11.
58. Horsburgh CR, Shea KM, Phillips P, Lavalley M. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials. 2013;28(14):88.
59. CDC. Drug-resistant TB. http://www.cdc.gov/tb/topic/drtb/Accessed May 5 2016.
60. Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, Feng PJ, Villarino E, Saukkonen J, Heilig CM, Weiner M, El-Sadr WM. Lessons from a randomized clinical trial for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(12):1582-7.